Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibitors of PARP: Number crunching and structure gazing
Johannes Rudolph, Karen Jung, Karolin Luger
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 11
Open Access | Times Cited: 85

Showing 26-50 of 85 citing articles:

Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells
Maria João Pires, Seher Alam, Alen Lovrić, et al.
Journal of Biological Chemistry (2025), pp. 108361-108361
Open Access
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
Jinge Zhao, Bo Tang, Pengfei Shen, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104698-104698
Closed Access
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced
Kaveri Goel, Vani Venkatappa, Kimiko L. Krieger, et al.
NAR Cancer (2025) Vol. 7, Iss. 2
Open Access
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
Andrés Poveda, Stéphanie Lheureux, Nicoletta Colombo, et al.
Gynecologic Oncology (2025) Vol. 197, pp. 74-82
Open Access
Slow Dissociation from the PARP1–HPF1 Complex Drives Inhibitor Potency
Petra Stojanovic, Karolin Luger, Johannes Rudolph
Biochemistry (2023) Vol. 62, Iss. 16, pp. 2382-2390
Open Access | Times Cited: 10
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)
Han Yu, Lei Wei
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-14
Open Access
Targeting DNA Damage Sensors for Cancer Therapy
Matthew R. Jordan, Pamela L. Mendoza-Munoz, Katherine S. Pawelczak, et al.
DNA repair (2025) Vol. 149, pp. 103841-103841
Open Access
Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities
Yosuke Yamada, Djeda Belharazem-Vitacolonnna, Hanibal Bohnenberger, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 11
Open Access | Times Cited: 15
Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model
Ellen 't Hart, John Bianco, Maaike A. C. Bruin, et al.
Journal of Controlled Release (2023) Vol. 357, pp. 287-298
Open Access | Times Cited: 9
Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time
Deja M. Brooks, Sudarshan Anand, Michael S. Cohen
Current Opinion in Chemical Biology (2023) Vol. 77, pp. 102402-102402
Open Access | Times Cited: 9
The function and regulation of ADP-ribosylation in the DNA damage response
Lena Duma, Ivan Ahel
Biochemical Society Transactions (2023) Vol. 51, Iss. 3, pp. 995-1008
Open Access | Times Cited: 8
Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging
Jyothi Mahadevan, Asmita Jha, Johannes Rudolph, et al.
iScience (2022) Vol. 26, Iss. 1, pp. 105779-105779
Open Access | Times Cited: 13
DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review
Zoe Phan, Caroline E. Ford, C. Elizabeth Caldon
Pharmacological Research (2023) Vol. 196, pp. 106927-106927
Open Access | Times Cited: 7
PARP inhibitors for prostate cancer
Ossian Longoria, Nick Beije, Johann S. de Bono
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 25-35
Open Access | Times Cited: 7
Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship
Amandeep Thakur, Mandeep Rana, Ritika Ritika, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106893-106893
Closed Access | Times Cited: 7
Human PARP1 Facilitates Transcription through a Nucleosome and Histone Displacement by Pol II In Vitro
E. Yu. Kotova, Fu‐Kai Hsieh, Han-Wen Chang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7107-7107
Open Access | Times Cited: 12
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair
Jodie Cropper, Dauren Alimbetov, Kevin T. G. Brown, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation
Flurina Böhi, Michael O. Hottiger
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1617-1617
Open Access | Times Cited: 2
Monitoring nucleolar-nucleoplasmic protein shuttling in living cells by high-content microscopy and automated image analysis
Marina Engbrecht, David Grundei, Asisa M Dilger, et al.
Nucleic Acids Research (2024) Vol. 52, Iss. 15, pp. e72-e72
Open Access | Times Cited: 2
CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos
Rita Sala, Hector Esquer, Timothy Kellett, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8590-8590
Open Access | Times Cited: 2
Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition
Xixi Lin, Aashish Soni, Razan Hessenow, et al.
Radiotherapy and Oncology (2024) Vol. 200, pp. 110475-110475
Open Access | Times Cited: 2
Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery
Sahani Sandalima Uthumange, Angie Jun Hui Liew, Xavier Chee Wezen, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 116, pp. 117980-117980
Open Access | Times Cited: 2
The fast-growing business of Serine ADP-ribosylation
Edoardo José Longarini, Ivan Matić
DNA repair (2022) Vol. 118, pp. 103382-103382
Closed Access | Times Cited: 11
PARP1 Incises Abasic Sites and Covalently Cross-links to 3′-DNA Termini via Cysteine Addition Not Reductive Amination
Xiaoying Wei, Kun Yang
Biochemistry (2023) Vol. 62, Iss. 10, pp. 1527-1530
Closed Access | Times Cited: 6
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Peter H. J. Slootbeek, Sofie H. Tolmeijer, Niven Mehra, et al.
Critical Reviews in Clinical Laboratory Sciences (2023) Vol. 61, Iss. 3, pp. 178-204
Open Access | Times Cited: 5

Scroll to top